Opinion on Company Issues in North America

Published within

« | ... | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Sun: seeking unity

Sun's Solaris operating system should be integrated with the company's software product release cycles by the end of 2003. The IT giant is attempting to exploit lingering hostility from Microsoft clients annoyed by new licensing changes - offering a total software purchase and usage price that is lower and more consistent than Microsoft's.

Published By Datamonitor
27 Feb 2003
CommentWire
CommentWire

E.On: European gas takes priority

Having suggested a large scale acquisition in the US was being planned in 2002, E.On has refocused its attention on its recent acquisition, Ruhrgas. Its aim is to first strengthen its operations in Germany and potentially build up its position in Eastern Europe's upstream market.

Published By Datamonitor
27 Feb 2003
CommentWire
CommentWire

Janssen: once-daily Reminyl too little too late

Janssen's new once-daily formulation of Reminyl will strengthen its position against market leader Aricept. But although the two drugs are very similar, what separates them is the formidable marketing power of Pfizer and Eisai that has propelled Aricept to near blockbuster status. Despite short term gains for Reminyl, Aricept will remain the leader for another five to ten years.

Published By Datamonitor
27 Feb 2003
CommentWire
CommentWire

Weight Watchers: booming revenues

US baby boomers are now a significant proportion of the dieting population. Diet service companies are responding by increasingly trying to attract this lucrative consumer segment. The development of new products directly marketed to these boomers - from these companies and traditional CPG manufacturers - will significantly drive the health category product and service industries.

Published By Datamonitor
27 Feb 2003
CommentWire
CommentWire

IDT: crossing the line

IDT is hoping that by raising security concerns it will stand a better chance of acquiring Global Crossing. Hutchison Telecommunications and Singapore Technologies Telemedia are currently in line to get the assets, but IDT CEO James Courter's experience as a congressman might help him to find the right political strings to pull.

Published By Datamonitor
26 Feb 2003
CommentWire
CommentWire

Egg: sunny side up in the US

Following its entry into France, UK Internet bank Egg has announced it is considering a product launch in the US. It will spend GBP5 million investigating opportunities in the US market and testing the Egg brand. However, despite Egg's seemingly unabated international ambition, there is a danger that the bank could be overstretching itself.<BR />

Published By Datamonitor
26 Feb 2003
CommentWire
CommentWire

Overture: fast attack on Google

Having just acquired AltaVista, Overture is now planning to pick up the web search business of Fast Search & Transfer. Fast Search will provide Overture with more advanced technology, while AltaVista provides patents, partners, engineers and customers. Fast, meanwhile, will at last get some cash from its loss-making unit. <BR />

Published By Datamonitor
26 Feb 2003
CommentWire
CommentWire

Timeline: a landmark judgment

A US superior court has found that Microsoft's right to sublicense Timeline's technology is "substantially limited"; this may result in extra costs for some of Microsoft's customers and partners. The court case may just have been Microsoft protecting its user base - but it could also be seen as aggressive action against a rival.

Published By Datamonitor
25 Feb 2003
CommentWire
CommentWire

PowderJect: Dukoral must catch the traveler's eye

PowderJect Pharmaceuticals has received Canadian marketing approval for its traveler's diarrhoea vaccine, Dukoral. The vaccine is orally administered and this will prove an advantage in terms of uptake success. However, compliance is typically low for travel vaccines and the company will need to adopt active promotional strategies to drive sales of the vaccine.

Published By Datamonitor
25 Feb 2003
CommentWire
CommentWire

Barr: AstraZeneca's grip on US tamoxifen market finally broken

AstraZeneca's estrogen analogue, tamoxifen, was originally launched in 1973 under the brand name Nolvadex. After almost three decades on the market, tamoxifen continues to be a core breast cancer treatment. Unsurprisingly, it is heavily genericized in most markets, except the US - until now. AstraZeneca will turn to its newer Arimidex to offset competition from generic tamoxifen.

Published By Datamonitor
24 Feb 2003

« | ... | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ... | » »|

No help is available.